Literature DB >> 11642546

Cell-type specific regulation of thrombospondin-1 expression and its promoter activity by regulatory agents.

S A Kim1, J H Kang, I Cho, S W Bae, K J Hong.   

Abstract

Thrombospondin-1 (TSP-1), a multifunctional protein that is able to function as a negative regulator of solid tumor progression and angiogenesis, is normally present at a very low level but rapidly elevated in pathological tissues. To understand the cellular regulation of TSP-1 expression, the mode of it's expression in Hep3B, SK-HEP-1, and porcine aortic endothelial (PAE) cells was examined in the presence of all-trans retinoic acid (ATRA), interleukin-6 (IL-6), interferon-gamma (IFN-gamma), or phorbol 12-myristate 13-acetate (PMA). ATRA or IL-6 induced a dose-dependent increase of TSP-1 protein and mRNA levels in PAE cells, while they negatively regulated TSP-1 expression in the Hep3B and SK-HEP-1 cells. In contrast, PMA showed just the opposite effects on the TSP-1 expression in the same cells. IFN-gamma had little effect on TSP-1 level in Hep3B and PAE cells. The TSP-1 expression in SK-HEP-1 cells by these agents showed a close resemblance to that of liver cells rather than that of the endothelial cell line. Possible TSP-1 promoter-mediated responses by ATRA, IL-6, IFN-gamma, or PMA in Hep3B and PAE cells examined with luciferase activity of TSP-LUC reporter plasmid showed that levels of TSP-1 promoter activity were lower than that of the expressed TSP-1 protein and mRNA levels. Transfection of c-Jun and/or RARalpha expression vectors into Hep3B and PAE cells resulted in the enhanced TSP-1 promoter activity as well as the increments of of its protein and mRNA level. These results suggest that regulatory agents-induced TSP-1 expression may be attributed to mRNA stability and/or translational activation in concert with transcriptional activation and TSP-1 expression may be independently controlled via each signal pathway stimulated by PMA or ATRA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642546     DOI: 10.1038/emm.2001.21

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  6 in total

1.  IL-6Ra in Smooth Muscle Cells Protects against Schistosoma- and Hypoxia-induced Pulmonary Hypertension.

Authors:  Claudia Mickael; Rahul Kumar; Daniel Hernandez-Saavedra; Biruk Kassa; Linda Sanders; Dan Koyanagi; Sue Gu; Michael H Lee; Rubin M Tuder; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

2.  Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts.

Authors:  Yoshihiro Mimura; Hironobu Ihn; Masatoshi Jinnin; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

3.  Matrix regeneration proteins in the hypoxia-triggered exosomes of shoulder tenocytes and adipose-derived mesenchymal stem cells.

Authors:  Finosh G Thankam; Isaiah Chandra; Connor Diaz; Matthew F Dilisio; Jonathan Fleegel; R Michael Gross; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2019-12-03       Impact factor: 3.396

Review 4.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

5.  Phospho-proteomic analysis of primary human colon epithelial cells during the early Trypanosoma cruzi infection phase.

Authors:  Shankar Suman; Girish Rachakonda; Sammed N Mandape; Shruti S Sakhare; Fernando Villalta; Siddharth Pratap; Maria F Lima; Pius N Nde
Journal:  PLoS Negl Trop Dis       Date:  2018-09-17

6.  Scalable Generation of Mesenchymal Stem Cells and Adipocytes from Human Pluripotent Stem Cells.

Authors:  Manale Karam; Ihab Younis; Noor R Elareer; Sara Nasser; Essam M Abdelalim
Journal:  Cells       Date:  2020-03-13       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.